Immunotherapy May Spare Surgery in Rare Rectal Cancer

“Immune-based treatments for cancer have become the biggest new advance in tackling tumors, and the latest approval could make a big difference for some people with rectal cancer. On Oct. 19, the U.S. Food and Drug Administration (FDA) approved dostarlimab (brand name: Jemperli) to treat a specific type of rectal cancer called microsatellite instability-high (MSI-H)/mismatch […] The post Immunotherapy May Spare Surgery in Rare Rectal Cancer appeared first on Human Progress.